 Diabetic Nephropathies
"Diabetic Nephropathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Descriptor ID |
D003928
|
| MeSH Number(s) |
C12.777.419.192 C13.351.968.419.192 C19.246.099.875
|
| Concept/Terms |
Diabetic Nephropathies- Diabetic Nephropathies
- Nephropathies, Diabetic
- Nephropathy, Diabetic
- Diabetic Nephropathy
- Diabetic Kidney Disease
- Diabetic Kidney Diseases
- Kidney Disease, Diabetic
- Kidney Diseases, Diabetic
Diabetic Glomerulosclerosis- Diabetic Glomerulosclerosis
- Kimmelstiel-Wilson Syndrome
- Kimmelstiel Wilson Syndrome
- Syndrome, Kimmelstiel-Wilson
- Kimmelstiel-Wilson Disease
- Kimmelstiel Wilson Disease
- Nodular Glomerulosclerosis
- Glomerulosclerosis, Nodular
- Glomerulosclerosis, Diabetic
- Intracapillary Glomerulosclerosis
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Nephropathies".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Nephropathies".
This graph shows the total number of publications written about "Diabetic Nephropathies" by people in this website by year, and whether "Diabetic Nephropathies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 2 | 0 | 2 | | 1992 | 2 | 2 | 4 | | 1993 | 4 | 2 | 6 | | 1994 | 4 | 0 | 4 | | 1995 | 3 | 3 | 6 | | 1996 | 4 | 0 | 4 | | 1997 | 6 | 3 | 9 | | 1998 | 5 | 1 | 6 | | 1999 | 1 | 2 | 3 | | 2000 | 5 | 1 | 6 | | 2001 | 1 | 0 | 1 | | 2002 | 4 | 2 | 6 | | 2003 | 9 | 2 | 11 | | 2004 | 6 | 4 | 10 | | 2005 | 3 | 1 | 4 | | 2006 | 3 | 1 | 4 | | 2007 | 7 | 1 | 8 | | 2008 | 6 | 1 | 7 | | 2009 | 4 | 16 | 20 | | 2010 | 8 | 2 | 10 | | 2011 | 4 | 4 | 8 | | 2012 | 2 | 0 | 2 | | 2013 | 4 | 2 | 6 | | 2014 | 5 | 3 | 8 | | 2015 | 4 | 2 | 6 | | 2016 | 6 | 0 | 6 | | 2017 | 2 | 0 | 2 | | 2018 | 7 | 2 | 9 | | 2019 | 6 | 0 | 6 | | 2020 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetic Nephropathies" by people in Profiles.
-
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 12 03; 383(23):2219-2229.
-
Bakris G. Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. J Fam Pract. 2020 09; 69(7 Suppl):S81-S86.
-
Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
-
Henriksen KJ, Chang A. The Importance of Nephropathology in Kidney Cancer. Semin Nephrol. 2020 01; 40(1):69-75.
-
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
-
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
-
Bakris GL. Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019 11; 74(5):573-575.
-
Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 10; 96(4):1030-1036.
-
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
-
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|